Endometrial Cancer Clinical Trials in San Antonio, Texas

21 studies are recruiting for endometrial cancer in San Antonio, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)

   Researchers are looking for new ways to treat people with proficient mismatch repair (pMMR) endometrial cancer (EC) that is advanced or recurrent. * EC is a type of cancer that starts in the tissues inside the uterus (womb) * pMMR indicates that certain normal proteins are present in the cancer cel…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology-San Antonio Medical Center ( Site 8001), San Antonio, Texas

   Locations

   264 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06952504 on ClinicalTrials.gov

2. A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

   This is a Phase 1/2, open-label, multicenter study evaluating the safety, tolerability, pharmacokinetics, pharmacodynamics and anti-tumor activity of TER-2013 in patients with advanced solid tumors harboring AKT/PI3K/PTEN pathway alterations.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research, San Antonio, Texas

   Locations

   20 in total

   Run by

   Terremoto Biosciences Inc.

   See if you can join NCT07109726 on ClinicalTrials.gov

3. The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

   The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, toler…

   Stage

   Phase 1

   Ages

   12 and older

   Site

   New Experimental Therapeutics of San Antonio - NEXT Oncology, San Antonio, Texas

   Locations

   77 in total

   Run by

   PMV Pharmaceuticals, Inc

   See if you can join NCT04585750 on ClinicalTrials.gov

4. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START - San Antonio, San Antonio, Texas

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

5. Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

   The purpose of this study is to compare how well Rina-S (GEN1184) works compared to treatment of physician's choice (paclitaxel or doxorubicin) that are considered standard medical care for the treatment of recurrent or progressive endometrial cancer (EC) following prior therapy. There is an equal …

   Stage

   Phase 3

   Ages

   18 and older

   Site

   USOR - TX Oncology - SA NE, San Antonio, Texas

   Locations

   171 in total

   Run by

   Genmab

   See if you can join NCT07166094 on ClinicalTrials.gov

6. DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

   DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progression free survival (PFS), as assessed by BICR, in participant…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, San Antonio, Texas

   Locations

   255 in total

   Run by

   AstraZeneca

   See if you can join NCT06989112 on ClinicalTrials.gov

7. A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

   This is a study to evaluate the safety and preliminary anti-tumor activity of STRO-004 in adults with metastatic cancer. This study includes 3 parts: * Part 1A is a dose escalation study of STRO-004 monotherapy in selected tumor types known to commonly express Tissue Factor (TF). * Part 1B is a coh…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   NEXT San Antonio, San Antonio, Texas

   Locations

   9 in total

   Run by

   Sutro Biopharma, Inc.

   See if you can join NCT07227168 on ClinicalTrials.gov

8. A Phase 1 Study of LNCB74 in Advanced Solid Tumors

   This is an open-label, phase 1, dose escalation and dose expansion study to determine safety and tolerability, and to determine the maximum tolerated dose and / or recommended phase 2 dose of LNCB74 in participants with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   UT Health San Antonio - MD Anderson Cancer Center, San Antonio, Texas

   Locations

   14 in total

   Run by

   NextCure, Inc.

   See if you can join NCT06774963 on ClinicalTrials.gov

9. A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

   The purpose of this open-label, first-in-human (FIH) trial is to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of DZR123 (Tulmimetostat, CPI-0209), both as monotherapy and in combination with enzalutamide, in patients with advanced solid t…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   South Texas Accelerated Research Therapeutics, San Antonio, Texas

   Locations

   80 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT04104776 on ClinicalTrials.gov

10. A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors

    This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Normunity Investigational Site, San Antonio, Texas

    Locations

    18 in total

    Run by

    Normunity AccelCo, Inc.

    See if you can join NCT07182149 on ClinicalTrials.gov

11. A Study of PHST001 in Advanced Solid Tumors

    This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced rela…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Center for Cancer Research - San Antonio, San Antonio, Texas

    Locations

    20 in total

    Run by

    Pheast Therapeutics

    See if you can join NCT06840886 on ClinicalTrials.gov

12. Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

    HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START - San Antonio, San Antonio, Texas

    Locations

    12 in total

    Run by

    Whitehawk Therapeutics, Inc.

    See if you can join NCT07444814 on ClinicalTrials.gov

13. A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

    This clinical trial is evaluating a drug called ART0380 in participants with advanced or metastatic solid tumors. The main goals of this study are to: * Find the recommended dose of ART0380 that can be given safely to participants alone and in combination with gemcitabine or irinotecan * Learn more…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Texas Oncology - San Antonio, San Antonio, Texas

    Locations

    82 in total

    Run by

    Artios Pharma Ltd

    See if you can join NCT04657068 on ClinicalTrials.gov

14. Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

    This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Texas Oncology San Antonio Medical Center, San Antonio, Texas

    Locations

    75 in total

    Run by

    Daiichi Sankyo

    See if you can join NCT07022483 on ClinicalTrials.gov

15. A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors

    This study will test the safety of a drug called PF-08046054/SGN-PDL1V alone and with pembrolizumab in participants with solid tumors. It will also study the side effects of this drug. A side effect is anything a drug does to your body besides treating your disease. Participants will have solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Virginia, LLC, San Antonio, Texas

    Locations

    62 in total

    Run by

    Seagen, a wholly owned subsidiary of Pfizer

    See if you can join NCT05208762 on ClinicalTrials.gov

16. Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors

    This is a phase 1/1b, open-label, multicenter study consisting of sequential parts designed to evaluate the safety, tolerability, and effects pharmacokinetic (PK) profile, and antitumor activity of RGT-490, an investigational oral therapy, in adults with locally advanced or metastatic solid tumors …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT San Antonio, San Antonio, Texas

    Locations

    5 in total

    Run by

    Regor Pharmaceuticals Inc.

    See if you can join NCT07524322 on ClinicalTrials.gov

17. A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors

    The purpose of this study is to evaluate the efficacy and safety of zanidatamab for the treatment of participants with previously treated solid tumors that have Human Epidermal Growth Factor Receptor 2 (HER2) Immunohistochemistry (IHC) 3+ overexpression.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology - San Antonio, San Antonio, Texas

    Locations

    28 in total

    Run by

    Jazz Pharmaceuticals

    See if you can join NCT06695845 on ClinicalTrials.gov

18. A Study of Lorigerlimab in Participants With Advanced Solid Tumors

    Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 80 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    START San Antonio, San Antonio, Texas

    Locations

    16 in total

    Run by

    MacroGenics

    See if you can join NCT06730347 on ClinicalTrials.gov

19. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

    This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    NEXT Oncology, San Antonio, Texas

    Locations

    6 in total

    Run by

    ModeX Therapeutics, An OPKO Health Company

    See if you can join NCT06239194 on ClinicalTrials.gov

20. A Study of DR-0202 in Patients With Locally Advanced or Metastatic, Relapsed or Refractory Carcinomas

    A phase 1a/1b, multicenter, open-label, dose escalation/expansion, multiple-dose study to evaluate the safety and activity of DR-0202 in patients with locally advanced or metastatic, relapsed or refractory carcinomas

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Dren Investigational Site, San Antonio, Texas

    Locations

    10 in total

    Run by

    Dren Bio

    See if you can join NCT06999187 on ClinicalTrials.gov

21. Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

    This study evaluates navtemadlin as maintenance treatment for patients with advanced or recurrent endometrial cancer (EC) who have achieved complete response or partial response on chemotherapy. The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Texas Oncology-San Antonio Medical Center, San Antonio, Texas

    Locations

    83 in total

    Run by

    Kartos Therapeutics, Inc.

    See if you can join NCT05797831 on ClinicalTrials.gov